ImmunoCellular Therapeutics Expands Manufacturing Relationship with Progenitor Cell Therapy, LLC for Dendritic Cell Vaccines
December 03 2013 - 6:00AM
Business Wire
New Process Development Improvements
Intended to Ensure Phase III and Commercial Readiness
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE
MKT:IMUC) announced the expansion of its relationship with
Progenitor Cell Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc.
(NASDAQ:NBS), for current good manufacturing practices (cGMP)
services for ImmunoCellular’s dendritic cell-based vaccines. PCT
currently manufactures ICT-121, a dendritic cell vaccine targeting
CD133 cells, in a phase I clinical trial for recurrent glioblastoma
multiforme (GBM) pursuant to a Services Agreement between the
companies. PCT also manufactured phase II clinical supplies of
ICT-107, a dendritic cell-based vaccine targeting six
tumor-associated antigens for newly diagnosed GBM. Under this newly
executed Services Agreement, PCT will manufacture clinical supplies
of ICT-140, a dendritic cell vaccine targeting seven ovarian cancer
antigens, using process improvements PCT will develop that can be
applied to the manufacture of all ImmunoCellular’s current vaccine
product candidates, ICT-107, ICT-121 and ICT-140. These process
improvements are intended to increase quality, consistency,
efficiency, and cost-effectiveness, and support ImmunoCellular’s
vaccine manufacturing requirements for conducting potential phase
III registration trials and for commercial manufacturing. PCT’s
facilities are registered with the FDA as human cells, tissues, and
cellular and tissue-based products (HCT/Ps) facilities, and
maintain GMP-compliant quality systems.
“Ensuring that ImmunoCellular has an established manufacturing
process that can support pivotal registration programs and eventual
commercial manufacturing for all our dendritic cell vaccines as
they advance toward registration is foundational for building a
leading cancer immunotherapy company,” said Andrew Gengos,
ImmunoCellular Chief Executive Officer. “We look forward to
continuing our partnership with PCT, and are pleased to be making
this investment in process enhancements now.”
About ImmunoCellular Therapeutics,
Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based
clinical-stage company that is developing immune-based therapies
for the treatment of brain and other cancers. ImmunoCellular is
conducting a phase II trial of its lead product candidate, ICT-107,
a dendritic cell-based vaccine targeting multiple tumor-associated
antigens for glioblastoma. ImmunoCellular’s pipeline also includes
ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a
dendritic cell vaccine targeting ovarian cancer antigens and cancer
stem cells. To learn more about ImmunoCellular, please visit
www.imuc.com.
Forward-Looking Statements for
ImmunoCellular Therapeutics
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
the risk that ICT-107, ICT-121 and ICT-140 can be further
successfully developed, manufactured or commercialized. Additional
risks and uncertainties are described in IMUC’s most recently filed
quarterly report on Form 10-Q and annual report on Form 10-K.
Except as permitted by law, IMUC undertakes no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.Investor RelationsJane
Green415-348-0010 direct415-652-4819 mobilejane@jmgcomm.com
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Mar 2024 to Apr 2024
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Apr 2023 to Apr 2024